Archived Newsletters

1. 10.30.26 -- What's Being Overlooked In Biopharma Manufacturing? 10/30/2026

   10/30/26 Outsourced Pharma Newsletter

2. 10.30.26 -- Escape The Biotech's Valley Of Death 10/30/2026
   10/30/26 Outsourced Pharma Newsletter
3. 10.29.26 -- OPCU: Navigating The Complexities Of ADC Development And Manufacturing 10/29/2026

   10/29/26 Outsourced Pharma Newsletter

4. 10.29.26 -- Early Developability Assessment Reduces Risk In Multi-Specific Antibody Programs 10/29/2026
   10/29/26 Outsourced Pharma Newsletter
5. 10.29.26 -- 6 Oligonucleotide Scale-Up Lessons For Sponsors 10/29/2026
   10/29/26 Outsourced Pharma Newsletter
6. 10.28.26 -- Accelerating Advanced Therapies: From Development To Manufacturing 10/28/2026

   10/28/26 Outsourced Pharma Newsletter

7. 10.28.26 -- Beyond Speed & Titer: Building Cell Lines That Scale 10/28/2026

   10/28/26 Outsourced Pharma Newsletter

8. 10.28.26 -- Earning Priority: How Biotechs Strengthen CDMO Relationships 10/28/2026
   10/28/26 Outsourced Pharma Newsletter
9. 10.27.26 -- From Pre-Filled Syringes To Commercial Fill-Finish Success 10/27/2026
   10/27/26 Outsourced Pharma Newsletter
10. 10.27.26 -- Reduce Bioprocessing Supply Risk With Manufacturing Closer To You 10/27/2026

    10/27/26 Outsourced Pharma Newsletter